Theorem Clinical Research

Drug Sponsors

Stratus Media Group acquires Paloma Pharmaceuticals and VasculoMedics

Monday, March 10, 2014 11:48 AM

Stratus Media Group (SMDI) has announced the acquisition, through merger, of two biotechnology companies, Paloma Pharmaceuticals, a developer of a non-steroidal, synthetic, small molecule drug library, and VasculoMedics, a platform epigenetic company that develops orally available small molecular inhibitors of zinc finger transcription factors.

More... »

NanoViricides denies $4.5B acquisition rumor

Monday, March 10, 2014 11:45 AM

NanoViricides, a development stage company creating special purpose nanomaterials for viral therapy, has denied a statement made in a blog post on the Seeking Alpha web site that it is being acquired for $2.25 billion to $4.5 billion.

More... »

TNI BioTech forms new subsidiary Cytocom

Thursday, March 6, 2014 03:58 PM

TNI BioTech, a biotech company working on chronic, life-threatening diseases, has formed a new subsidiary, Cytocom, for developing Low Dose Naltrexone (LDN) and Met-enkephalin (MENK).

More... »

Xenetic Biosciences opens headquarters, R&D facility

Wednesday, March 5, 2014 01:19 PM

Xenetic Biosciences, a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, has opened its new corporate headquarters and R&D facility in Lexington, Mass. Xenetic relocated its global headquarters to Lexington from London.

More... »

Human Longevity launched to promote healthy aging

Wednesday, March 5, 2014 01:13 PM

Human Longevity (HLI), a genomics and cell therapy-based diagnostic and therapeutic company focused on extending the healthy, high-performance human life span, has been launched by co-founders J. Craig Venter, Ph.D., Robert Hariri, M.D., Ph.D., and Peter H. Diamandis, M.D.

More... »

Bayer to acquire Dihon Pharmaceutical in China

Thursday, February 27, 2014 12:30 PM

Bayer plans to acquire Dihon Pharmaceutical Group, a privately held pharmaceutical company based in Kunming Yunnan, China, specializing primarily in over-the-counter (OTC) and herbal traditional Chinese medicine (TCM) products.

More... »

Emergent BioSolutions completes acquisition of Cangene

Monday, February 24, 2014 10:13 AM

Emergent BioSolutions, a specialty pharmaceutical company offering specialized products to healthcare providers and governments, has completed its acquisition of Cangene for $222 million in cash. After payment by Cangene of transaction related costs, Emergent expects to receive approximately $40 million of cash from Cangene in connection with closing. The completion of the acquisition follows the successful conclusion of all closing conditions, including approval by the Ontario Superior Court of Justice and a positive vote by Cangene shareholders at a special shareholder meeting held Feb. 12. The transaction is consistent with Emergent’s growth plan in that it diversifies the company’s revenue mix, adds commercial product sales and contributes to earnings growth.

More... »

Actavis to acquire Forest Laboratories for $25 billion

Tuesday, February 18, 2014 10:39 AM

Dublin-based Actavis has agreed to acquire Forest Laboratories of New York for a combination of cash and equity valued at approximately $25 billion.

More... »

Report: Strong Q4 M&A momentum expected to continue into 2014

Wednesday, February 12, 2014 01:44 PM

Pharmaceutical and life sciences (PLS) merger and acquisition volume and value increased in the fourth quarter of 2013, finishing the year for deal activity on a high note,according to Pharmaceutical and Life Sciences Deals Insights Quarterly, a quarterly analysis of M&A trends and outlook for the PLS sector issued by PwC. PwC’s Health Industries Group is an advisor to public and private organizations across the health industries.

More... »

Mallinckrodt to acquire Cadence Pharmaceuticalsfor $1.3 billion

Wednesday, February 12, 2014 01:26 PM

A subsidiary of Mallinckrodt, a global specialty pharmaceuticals company, will acquire Cadence Pharmaceuticals, and will commence a tender offer to acquire all outstanding shares for $14 per share in cash, or approximately $1.3 billion, a 32% premium to the trailing 30-trading-day volume weighted average price of $10.62 per share.

More... »

Subscribe to The CenterWatch Monthly



Browse by:


October 20

Toronto Star, with FDA data, exposes weaknesses in Health Canada's clinical trial, inspection oversight

Crowdsourcing effort aims to fund updated online social media guide for sponsor interaction with patients

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs